Journal article
Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.
Abstract
e19077
Background: We investigated the impact of mutation fraction, tumour sample cellularity, and diagnostic specimen type on EGFR TKI response, time to treatment failure (TTF) and overall survival in advanced EGFR mutation positive NSCLC patients. Methods: From March 2010 to May 2012, EGFR testing in the province of Ontario (Canada) was conducted at a single centre, using fragment analysis for exon 19 deletion and Sau961 …
Authors
Martin P; Shiau CJ; Pasic MD; Tsao MS; Kamel-Reid S; Le L; Higgins BP; Cheng SY; Burkes RL; Ng M
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. e19077–e19077
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.e19077
ISSN
0732-183X